Phase III
Merck, known as MSD outside of the U.S. and Canada, announced on Wednesday that it has seen positive results regarding the safety, tolerability and immunogenicity of V114 in two Phase III studies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 11, 2020.
In July, the study was paused after another patient experienced neurological issues.
The trial of Ninlaro drug for multiple myeloma did not meet statistical significance for the primary endpoint of progression-free survival (PFS).
Preclinical data for Pfizer and BioNTech’s Phase II/III COVID-19 mRNA vaccine candidate generated BNT162b2 strong anti-viral effects against an infectious SARS-CoV-2 challenge.
This morning, Dublin-based Amryt said the primary endpoint of the late-stage study was met. Look at what else the phase III trial of Filsuvez depicted.
Lenabasum is an oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2).
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
Results from a Phase III open-label extension trial showed that the safety and efficacy profile observed in previous Dupixent trials were maintained for up to three years in adults and adolescents with moderate-to-severe asthma.
Ai in medical field is helping the researchers at clinical stage research by increasing the efficiency, refining endpoints and quantifying pain, and much more.
PRESS RELEASES